Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

Robert K Hills, DPhil, Claire M Lucas, Laura J Scott, Natasha Carmell, Alison K Holcroft, Richard E. Clark, MD

Blood (2015) 126 (23): 1396.

https://doi.org/10.1182/blood.V126.23.1396.1396

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Blood (2015) 126 (23): 2780.

https://doi.org/10.1182/blood.V126.23.2780.2780

Published: 2015

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

Richard A. Larson, Dong-Wook Kim, MD PhD, Surapol Issaragrilsil, MD, Philipp le Coutre, MD, Pedro Enrique Dorlhiac Llacer, Gabriel Etienne, MD PhD, Richard E. Clark, MD, Ian Flinn, Hirohisa Nakamae, Andreas Hochhaus, MD, Giuseppe Saglio, MD, Hagop M. Kantarjian, Breanne Donohue, PharmD, Weiping Deng, PhD, Hans D. Menssen, MD PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4541.

https://doi.org/10.1182/blood.V124.21.4541.4541

Published: 2014

Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Blood (2014) 124 (21): 4512.

https://doi.org/10.1182/blood.V124.21.4512.4512

Published: 2014

Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.

Blood (2013) 122 (21): 2826.

https://doi.org/10.1182/blood.V122.21.2826.2826

Published: 2013

Journal Articles

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Jane F Apperley, MD, Richard M Szydlo, PhD, Gareth Gerrard, PhD, James R McCue, Jamie Wardle, Richard E Clark, MD, Stephen G O'Brien, Letizia Foroni, MD

Blood (2013) 122 (21): 93.

https://doi.org/10.1182/blood.V122.21.93.93

Published: 2013

Journal Articles

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

Emilian Snarski, John A Snowden, MD, FRCP, FRCPath, Manuela Badoglio, Kristina Carlson, Joachim Burman, MD, Maria Carolina Oliveira, John Moore, Jeffrey Tan, Montserrat Rovira, MD, Richard E Clark, MD, Albert Saiz, Sondess Hadj Khelifa, Alessandra Crescimanno, Lynne Laing, Maurizio Musso, Thierry Martin, Dominique Farge, MD

Blood (2013) 122 (21): 4640.

https://doi.org/10.1182/blood.V122.21.4640.4640

Published: 2013

Journal Articles

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Jacob Grinfeld, Juan M Alonso-Dominguez, Mary Alikian, Mikel Valgañón, PhD, Georgios Nteliopoulos, PhD, Deborah L. White, PhD, FFSc(RCPA), David Marin, Corinne Hedgley, Stephen O'Brien, Richard E. Clark, MD, Richard M Szydlo, Jane Apperley, John M Goldman, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 2555.

https://doi.org/10.1182/blood.V120.21.2555.2555

Published: 2012

Journal Articles

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Juan M. Alonso-Dominguez, Sr., MD, Jacob Grinfeld, MD, Mary Alikian, David Marin, Alistair Reid, PhD, Mustafa Daghistani, Jane Apperley, John M Goldman, MD, Corinne Hedgley, Steve O‘Brien, Richard E. Clark, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 875.

https://doi.org/10.1182/blood.V120.21.875.875

Published: 2012

Journal Articles

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Richard A. Larson, MD, Udomsak Bunworasate, MD, Anna G. Turkina, MD, PhD, Stuart L. Goldberg, MD, Pedro Dorlhiac-Llacer, MD, Jose L. Lopez, MD, Hagop M. Kantarjian, Giuseppe Saglio, MD, Andreas Hochhaus, MD, Albert Hoenekopp, MD, Rick E. Blakesley, PhD, Richard Yu, Neil J. Gallagher, MD, PhD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS

Blood (2011) 118 (21): 3768.

https://doi.org/10.1182/blood.V118.21.3768.3768

Published: 2011

Journal Articles

Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,

Gordon Cook, Keiren Kirkland, Julia Lee, Rachel M Pearce, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Richard E. Clark, MD, Stephen Mackinnon, MD, David I. Marks, MBBS, PHD

Blood (2011) 118 (21): 4125.

https://doi.org/10.1182/blood.V118.21.4125.4125

Published: 2011

Journal Articles

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, MD, Philipp D. le Coutre, MD, Josy Reiffers, Ricardo Pasquini, MD, Clarisse Lobo, MD, Richard E. Clark, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Ariful Haque, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 207.

https://doi.org/10.1182/blood.V116.21.207.207

Published: 2010

Journal Articles

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Surapol Issaragrisil, MD, FRCP, FACP, FRCPA, FRCPath, Philipp D. le Coutre, MD, Josy Reiffers, MD, Clarisse Lobo, MD, Ricardo Pasquini, MD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Mei Dong, MD, MS, Ariful Haque, MS, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2009) 114 (22): LBA-1.

https://doi.org/10.1182/blood.V114.22.LBA-1.LBA-1

Published: 2009

Journal Articles

Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.

Lihui Wang, MD, Athina Giannoudis, PhD, Steven Lane, PhD, Paula R. Williamson, PhD, Munir Pirmohamed, PhD, Richard E. Clark, MD

Blood (2006) 108 (11): 2145.

https://doi.org/10.1182/blood.V108.11.2145.2145

Published: 2006

Journal Articles

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD

Blood (2005) 106 (11): 1094.

https://doi.org/10.1182/blood.V106.11.1094.1094

Published: 2005

NARROW

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent

Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation,

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Clinical and Functional Evidence That Drug Transporter Expression Dictates the Response to Imatinib in Chronic Myeloid Leukaemia.

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only